the world changed in an instant that we were ready. internet traffic soared and we've never slowed down. schools and businesses went virtual and we powered a new reality because we are built to keep you ahead.

thanks for joining us. i'm the white house monkeypox response. today i'm joined by doctor fauci, doctor wilensky. before i turn to my colleagues i want to provide an update on the progress we are making in combating monkeypox. we continue to leverage every capability and partner with leaders ongr the ground to meet people where they are with vaccines, tests, treatments and information. the last couple of weeks a large event pilot has been incredibly successful over 3300 shots were administered in new orleans. over 1,000 shots were administered oakland provided over 4,000 shots at black friday in atlanta. and we recently were notified

that the administrator had an additional dose in the days and events following the pride last month. a total of vaccine administration as part of the pilot program to 11,000 doses who might not have otherwise gotten a shot we continue to build on this work for large and small across the a country which we will talk about more. stepping backee we are seeing te impact of the administration's comprehensive strategy in the latest case trends and other promising data points. overall a new case numbers are down 50% sincegu early august ad in places like atlanta whereth we've worked closely with the

public health community and information around events like black pride, the cases have steadily declined and in dc 20% on average per week since the peak in mid july and knowledge of the tools and interests have increased. more than two thirds understand the risk profilepo and behavior and nearly three quarters said they would get vaccinated if exposed. this shows the work to expand knowledge in the tool to fight it alongside so many local enhealth departments and other community organizations is working. we know there's a lot more to do

especially for black and brown communities where thee burdenrk remains high, but there's no question the work we've done to increase the vaccine supply and get people vaccinated, wrap up the availability of testing and treatments and educate individuals on how they can protect themselves is making a tremendous difference. this strategy is working and as will hear from doctor fauci, we will continue to work nonstop to get more shots in arms, more information to the highest risk individuals and learn as much as we can about the virus in our treatment so we can quickly and effectively end this outbreak. let me turn over to doctor fauci whori will talk about clinical trials launched to make sure we can effectively treat those that have contracted the virus.gi >> talking to you and giving a

brief overview in the first slide of the research priorities for monkeypox, which generally and broadly fall under five major pillars there are a number of unanswered questions, so as we implement the interventions that we have understanding better transmission as well as the issue of animal reservoirs but also globally and the importance off developing the diagnostics to be able to determine if we see a person in the asymptomatic or presymptomatic stage doesn't have an obvious legion is there a test we can do to alert us to

that and therefore help stop tht spread and also to evaluate new treatments i'm going to speak about one of the treatments that wee have and the development of other antiviral drugs and finallyy to optimize the regiments what i'm going to mention are two significant clinical trials. one in the therapeutics and one here in the united states and one internationally and then also to take a look at the vaccine studies that we are doing in the united states we are conducting and it's already started on september 8th the u

retrial that is referred to as the standing for the study as you know it is approved by the animal rule but it is under expanded access so the plan will involve 60 clinical sites in the united states with a targeted enrollment of 530 people. we are going to randomize people-1. a very important aspect of this that we learned from our experience back in the age of hiv is to get the community and involved in being able to determine what is best for them so in the trial there's an open label segment that will enroll

people at risk such as pregnant individuals and others withwi severe disease so if a person comes in and has a severity of disease they can be in the trial but in an open label component that means they will receive and more information about the trial is shown on the link on the slide. in addition to that we are dealing with a phase three trial in the democratic republic of the congo and recalled when you at the different slaves it has a higher degree of mortality theyey experience compared to te low degree of mortality van are currently in the united states. this again is a randomized

double-blind trial. the target is 450 adults and children with 3 kilograms or more with laboratory concerns. pregnant women are eligible in this particular study because of the risk that is ongoing and actually practical now and the participants will be randomized and assigned to either for the two times. given the severity of the disease. next slide and finally a trial

for the administration it opened on september 8th and the t targt is 200 individuals from 18 to 50. at the participants are going to be signed at random to one of three either the standard regimen but they will be two separate doses of one to five of the standard dose, that's the one that was recently authorized and then the standard dose administered. in the united states we have enough doses to handle the people at risk but this is a global problem and we are going

to make a contribution of one to ten works that will immediately double the amount of doses available on the international scale and will determine if they are at least as good as the responses introduced with regards to the regimen. also there will be additional data on the safety and tolerability of the regimen and then it finally more information on the trials can be seen on clinical trials. with that i will hand it over. >> thank you, doctor fauci and good morning. i would like to share the data out of the cdc on the algebraic as of september 14th over 59,600 cases have been detected globally there been 23,000 cases

identified across all 50 states we've been pleased to see a decline here and abroad so there are areas where the rate is still increasing. we approached the news with cautious optimism. the work being done to vaccinate at risk individuals and people who've made informed decisions to make temporary changes to their behavior to protect themselves and their community we recognize however we must continue to aggressively respond to theol entire toolkit. over the past several weeks we have also seen the racial and ethnic makeup of this outbreak evolve.

representing 25% of cases and non-hispanic white men represented 26% of cases. weo continue to monitor on this outbreak and how prevention measures are being used. yesterday cdc posted new data by jurisdiction. in addition to reporting the aggregate data for the total number for race and ethnicity they display the total doses for each of the individual jurisdictions for which we have received data. we continue to work closely more

people have become eligible for the second dose specifically 28 days after the first dose. as a reminder it is a two dosee of vaccine and it's important to receive the second dose in the series to have protection against monkeypox that suggest it is 14 days after the second dose. to provide the most complete picture of who is getting vaccinated we've been able to receive data on race and ethnicity for 91% of the first dose was reported. among those reported to those that are white represent about 47% and those who are hispanic about 21% and of those who are black represent about 12%. given the date i shared earlier the percentage of the vaccines administered to latinos or hispanic men and non-hispanic black man or disproportionately

lower the end we are seeing represented in cases. it's critical education, vaccination, testing and treatment are equally accessible to all populations but especially those most affected by this outbreak. to collaborate with jurisdictions for health disparities in the effort to efo allocate the vaccines more equitably. we've already had success with this approach for the vaccination at large that was announced on august 18th. so far through this program, the monkeypox vaccines have been administered to over 10,000

people lacked large events and at the oakland pride fest. this vaccine equity pilot program will expand these efforts to engage with communities in smaller events and intervention on addressing disparities. the application process is open and available. in all the work we do to launch the program and the opportunity for the equity it presents thank you and i will now turn it over. with cases regularly trending down nearly 50% since the peak in early august while there's

more work we are doing to reach all the communities at the highest risk i want to be clear this is the result of our work together to increase the availability and use of testing to make vaccines readily available to those that can benefit most providing guidance on how to avoid monkeypox into the community has done it but as we are hearing the work is far from over. as we've said equity must remain the cornerstone of the response and currently some jurisdictions are seeking the rate of infection while others are seeing a decline. we also see the cases are concentrated and others that have men of color vaccines have been administered to white men. they've begun or completed the series and we are entering the phase of the vaccination campaign to continue to get the

first doses into arms for second doses. to use the strategies that left us reachnt deeper into the community. to those that might not have sought to services and more traditional places, 63% of the vaccines allocated have gone into arms. in georgia nearly 70% of the people who were vaccinated antiblack pride identified as nonwhite and nearly 50% of the vaccines administered were two black people. these interventions are working and as the word we have more coming. as i said before, the youth's large-scale events are one lever but we know the sustained outrage will make the difference. that's why today as you heard we are opening applications for the second equity intervention pilot that focuses on smaller projects to help us reach the communities

we need to link to the vaccines, education, testing and treatment.ne health departments use the local experience and connection to the community to identify the hyper- local strategies to improve the vaccine access across color specifically those that are overrepresented in the outbreak. cdc will providec. them with vaccines, materials and technical assistance needed to realize the interventions and help us learn. as a set of the application is going to be available on the website and of the administration will be promoting the pilot program to the direct communication with partners as well as through social media. the data tells us monkeypox is not an infection that exists in

isolation. it travels with hiv and other infections. published last week tells us 61% of people diagnosed with monkeypox either had hiv oriented sti. we used the data to change how monkeypox surfaces can be supported by public health departments, clinics and community-based organizations. last week the cdc communicated to the departments and directly funded hiv community-based organizations that the hiv and std dollars could be used to help us and the outbreak. at the same people we need to test for hiv and infections and lead to prevention and care or the same people who need monkeypox related to surfaces like testing, education and vaccines. this changing guidance to

recipients community-based organizations. to help us do better for the exact same population. this is just the latest example of us being responsive to what's happening on the ground and pivoting our focus and resources where they are most needed. thank you.. >> a few questions. first, afp. the trends look good. what do you attribute that and how confident are you that will keep anna secondary to that what

is your concern level, thank you. >> first, we should note we've made strong progress. we are keeping pedal to the metal as we continue the vigilance. what do i attribute it to come of the multilayered approach of all the things we are doing. the testing, the massive amounts of education and outreach, the vaccinations we've been able to get out and as noted to get the harder to reach communities to those that might not have been first in line and that is where we are right now with all these pilot activities.

>> this is a toolkit and a lesson we've learned from so many others including hiv so i think that again the behavior change, the vaccines, the testing, the messaging and equity focus will lead us to the control of the outbreak. it's not those that are transmitting so knowledge is important, anxiety is not also be aware that this is what matters. >> sorry to miss the second part of the question. we had a guidance and calls with educators and university presidents and health educators

to make sure they know what they are looking for should a patient come in. we've seen should there be a single case we don't see the extension of the cases in those settings. we will take another question. >> you said you are giving the gas on the pedal and not ensuring they continue to go down. i'm wondering the strategy now that it's going forward

continuing to make sure the vaccine uptake continues to approve and we continue to vaccinate especially those thath are hardest to reach and bring the vaccine to the interventions but let me turn to doctor wilensky first to speak in more detail about some of those efforts. every single one of the large events there's been a massive amount of research and education and folks on the ground and how they can protect themselves and what behaviors might lead to more infections and how they might change and of the more and more we do that the more the knowledge increases. we see the communities understand how to protect

themselves and the behaviors. they understand how it could decrease risk so it's to both providers and clinicians and to the community. >> i will start by saying what is surprising is the strategy here is working. i think they've been clear that it's about education, testing, treatment and vaccines. you don't use one tool in the tool kit, you use all the tools and i think we have some positive reviews from that study from pennsylvania that shows the messaging is coming through and some cautiously optimistic news from what we are seeing with members. ..

the community has their foot on the gas pedal and helping us to address the outbreak and the research that we need so we understand how to use tpoxx and vaccines. so it is an all of society effort and kudos for putting their foot on the pedal. >> kevin, another question. >> chris johnson. >> thanks for taking this call. you talk about the call on one hand, equity has been a primary focus in the monkeypox outbreak and seeing numbers where new cases are shifting increasing among men of color. why do you think these efforts

of increased efforts for equity are not having an effect >> . >> . >> that this effort is

unprecedented in terms of reaching these communities. so i think for the cdc all of our commitment in the administration is to focus efforts on equity to resolve i the issue we see. there is a hard effort and a challenge and a a way to address equity is intentionally and this is intentional. >> we have another question? >> i have a question. doctor archie, on —- doctor fauci

with the things that i'm talking about.

first they are dramatically down so i am wondering if you have any on the ground feedback about why that is happening? some positions for community workers? is there a feeling that is cases go down people don't feel like the urgency is gone or they are concerned? > let's talk with the cdc. >> so this happens when we rolled out other vaccines as well be other people who roll up their sleeves they are anxious to get this and then weaning off the interest in

vaccines that is the hard work. that's what we have to do the outreach we are just accustomed and we have learned some lessons how we have done it during covid we are taking our lessons learned doing the hard work of community outreach we have seen success through doing so with the large equity events. >> and with the question of resistance whenever you have a a viral illness that spreads with replication in the community with a single drug you are using there is always the theoretical possibility of resistance and why we're uncomfortable when you only have a single drug that has been shown to have efficacy or you are proving that has efficacy as part of the clinical trial. that's are putting effort of other targets of the

replication cycle. >> just one thing to add that the recent announcement from cdc about flexibility with the kjv std resources is an important lesson we are not working with us in isolation so as we continue to do the important hiv std work is all part of a strategy to make sure we are able to reach deeper in the community whether large events are using infrastructure with demonstrated effectiveness all of that is in the mix to make sure we get education to people and vaccine in people's arms. >> our local jurisdictions have no resources specific for the parks not only did we have to move those around but they have been stretched thin with

the resources available to them to address this outbreak. so first of all kudos to them for what they t have been able to do and achieve speaks to the need for supplemental funds. >> so this administration has made tremendous progress to the fight against monkeypox and we will use every tool to do that but thank you for your questions have a good day.